The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Eun-Jung | - |
dc.contributor.author | Kim, Hyungjin | - |
dc.contributor.author | Jung, Seung Min | - |
dc.contributor.author | Sung, Yoon-Kyoung | - |
dc.contributor.author | Baek, Han Joo | - |
dc.contributor.author | Lee, Jisoo | - |
dc.date.available | 2020-03-03T06:43:27Z | - |
dc.date.created | 2020-02-24 | - |
dc.date.issued | 2020-01 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/17658 | - |
dc.description.abstract | Biological disease-modifying antirheumatic drugs (bDMARDs) are highly effective agents for the treatment of inflammatory arthritis; however, they also possess a potential risk for serious infection. Recently, with the rapid expansion of the bD-MARDs market in Korea, reports of serious adverse events related to the agents have also increased, necessitating guidance for the use of bDMARDs. Current work entitled, "Expert consensus for the use of bDMARDs drugs for inflammatory arthritis in Korea," is the first to describe the appropriate use of bDMARDs in the management of inflammatory arthritis in Korea, with an aim to provide guidance for the local medical community to improve the quality of clinical care. Twelve consensus statements regarding the use of bDMARDs for the management of rheumatoid arthritis and ankylosing spondylitis were generated. In this review, we provide detailed guidance on bDMARDs use based on expert consensus, including who should prescribe, the role of education, indications for use, and monitoring strategies for safety. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.subject | ANTITUMOR-NECROSIS-FACTOR | - |
dc.subject | ACTIVE RHEUMATOID-ARTHRITIS | - |
dc.subject | B-VIRUS REACTIVATION | - |
dc.subject | RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | - |
dc.subject | RECEIVING CONCOMITANT METHOTREXATE | - |
dc.subject | INTERLEUKIN-6 RECEPTOR INHIBITION | - |
dc.subject | ADALIMUMAB PLUS METHOTREXATE | - |
dc.subject | FACTOR MONOCLONAL-ANTIBODY | - |
dc.subject | PLACEBO-CONTROLLED TRIAL | - |
dc.subject | HBSAG-POSITIVE PATIENTS | - |
dc.title | The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000505206100004 | - |
dc.identifier.doi | 10.3904/kjim.2019.411 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.35, no.1, pp.41 - 59 | - |
dc.identifier.kciid | ART002538487 | - |
dc.identifier.scopusid | 2-s2.0-85077863401 | - |
dc.citation.endPage | 59 | - |
dc.citation.startPage | 41 | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 35 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Baek, Han Joo | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Expert consensus | - |
dc.subject.keywordAuthor | Biological disease-modifying antirheumatic drugs | - |
dc.subject.keywordAuthor | Inflammatory arthritis | - |
dc.subject.keywordAuthor | Arthritis | - |
dc.subject.keywordAuthor | rheumatoid | - |
dc.subject.keywordAuthor | Spondylitis | - |
dc.subject.keywordAuthor | ankylosing | - |
dc.subject.keywordPlus | ANTITUMOR-NECROSIS-FACTOR | - |
dc.subject.keywordPlus | ACTIVE RHEUMATOID-ARTHRITIS | - |
dc.subject.keywordPlus | B-VIRUS REACTIVATION | - |
dc.subject.keywordPlus | RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | - |
dc.subject.keywordPlus | RECEIVING CONCOMITANT METHOTREXATE | - |
dc.subject.keywordPlus | INTERLEUKIN-6 RECEPTOR INHIBITION | - |
dc.subject.keywordPlus | ADALIMUMAB PLUS METHOTREXATE | - |
dc.subject.keywordPlus | FACTOR MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | HBSAG-POSITIVE PATIENTS | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.